|
 |
|
|||||||
|
|||||||||
© 2002 by the American Diabetes Association, Inc.
Bedtime Administration of NN2211, a Long-Acting GLP-1 Derivative, Substantially Reduces Fasting and Postprandial Glycemia in Type 2 Diabetes
1 Medical Department M (Endocrinology and Diabetes), Århus University Hospital, Århus, Denmark
2 Novo Nordisk A/S, Bagsværd, Denmark
3 Department of Medicine, General Clinical Research Center and Center for Biometrical Technology, University of Virginia, Charlottesville, Virginia
4 Institute of Clinical Pharmacology, University of Århus, Århus, Denmark
Glucagon-like peptide 1 (GLP-1) is a potent glucose-lowering agent of potential interest for the treatment of type 2 diabetes. To evaluate actions of NN2211, a long-acting GLP-1 derivative, we examined 11 patients with type 2 diabetes, age 59 ± 7 years (mean ± SD), BMI 28.9 ± 3.0 kg/m2, HbA1c 6.5 ± 0.6%, in a double-blind, placebo-controlled, crossover design. A single injection (10 µg/kg) of NN2211 was administered at 2300 h, and profiles of circulating insulin, C-peptide, glucose, and glucagon were monitored during the next 16.5 h. A standardized mixed meal was served at 1130 h. Efficacy analyses were performed for the fasting (7–8 h) and mealtime (1130–1530 h) periods. Insulin secretory rates (ISR) were estimated by C-peptide deconvolution analysis. Glucose pulse entrainment (6 mg · kg-1 · min-1 every 10 min) was evaluated by 1-min sampled measurements of insulin concentrations from 0930 to 1030 h and subsequent time series analysis of the insulin concentration profiles. All results are given as NN2211 versus placebo; statistical analyses were performed by analysis of variance. In the fasting state, plasma glucose was significantly reduced (6.9 ± 1.0 vs. 8.1 ± 1.0 mmol/l; P = 0.004), ISR was increased (179 ± 70 vs. 163 ± 66 pmol/min; P = 0.03), and plasma glucagon was unaltered (19 ± 4 vs. 20 ± 4 pg/ml; P = 0.17) by NN2211. Meal-related area under the curve (AUC)1130–1530 h for glucose was markedly reduced (30.6 ± 2.4 vs. 39.9 ± 7.3 mmol · l-1 · h-1; P < 0.001), ISR AUC1130–1530 h was unchanged (118 ± 32 vs. 106 ± 27 nmol; P = 0.13), but the increment (relative to premeal values) was increased (65 ± 22 vs. 45 ± 11 nmol; P = 0.04). Glucagon AUC1130–1530 h was suppressed (77 ± 18 vs. 82 ± 17 pmol · l-1 · h-1; P = 0.04). Gastric emptying was significantly delayed as assessed by AUC1130–1530 h of 3-ortho-methylglucose (400 ± 84 vs. 440 ± 70 mg · l-1 · h-1; P = 0.02). During pulse entrainment, there was a tendency to increased high frequency regularity of insulin release as measured by a greater spectral power and autocorrelation coefficient (0.05 < P < 0.10). The pharmacokinetic profile of NN2211, as assessed by blood samplings for up to 63 h postdosing, was as follows: T1/2 = 10.0 ± 3.5 h and Tmax = 12.4 ± 1.7 h. Two patients experienced gastrointestinal side effects on the day of active treatment. In conclusion, the long-acting GLP-1 derivative NN2211 effectively reduces fasting as well as meal-related (
12 h postadministration) glycemia by modifying insulin secretion, delaying gastric emptying, and suppressing prandial glucagon secretion.
CiteULike 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  W. P. Esler, J. Rudolph, T. H. Claus, W. Tang, N. Barucci, S.-E. Brown, W. Bullock, M. Daly, L. DeCarr, Y. Li, et al. Small-Molecule Ghrelin Receptor Antagonists Improve Glucose Tolerance, Suppress Appetite, and Promote Weight Loss Endocrinology, November 1, 2007; 148(11): 5175 - 5185. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. E. Dunning and J. E. Gerich The Role of {alpha}-Cell Dysregulation in Fasting and Postprandial Hyperglycemia in Type 2 Diabetes and Therapeutic Implications Endocr. Rev., May 1, 2007; 28(3): 253 - 283. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. L. Wajchenberg {beta}-Cell Failure in Diabetes and Preservation by Clinical Treatment Endocr. Rev., April 1, 2007; 28(2): 187 - 218. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Hinnen, L. L. Nielsen, A. Waninger, and P. Kushner Incretin Mimetics and DPP-IV Inhibitors: New Paradigms for the Treatment of Type 2 Diabetes J Am Board Fam Med, November 1, 2006; 19(6): 612 - 620. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. L. Baggio, D. Holland, J. Wither, and D. J. Drucker Lymphocytic Infiltration and Immune Activation in Metallothionein Promoter-Exendin-4 (MT-Exendin) Transgenic Mice Diabetes, June 1, 2006; 55(6): 1562 - 1570. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. F. Burkey, X. Li, L. Bolognese, B. Balkan, M. Mone, M. Russell, T. E. Hughes, and P. R. Wang Acute and Chronic Effects of the Incretin Enhancer Vildagliptin in Insulin-Resistant Rats J. Pharmacol. Exp. Ther., November 1, 2005; 315(2): 688 - 695. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Fehse, M. Trautmann, J. J. Holst, A. E. Halseth, N. Nanayakkara, L. L. Nielsen, M. S. Fineman, D. D. Kim, and M. A. Nauck Exenatide Augments First- and Second-Phase Insulin Secretion in Response to Intravenous Glucose in Subjects with Type 2 Diabetes J. Clin. Endocrinol. Metab., November 1, 2005; 90(11): 5991 - 5997. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. V Joy, P. T Rodgers, and A. C Scates Incretin Mimetics as Emerging Treatments for Type 2 Diabetes Ann. Pharmacother., January 1, 2005; 39(1): 110 - 118. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J. Holst and C. Orskov The Incretin Approach for Diabetes Treatment: Modulation of Islet Hormone Release by GLP-1 Agonism Diabetes, December 1, 2004; 53(suppl_3): S197 - S204. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. T. Bloomgarden Gut-Derived Incretin Hormones and New Therapeutic Approaches Diabetes Care, October 1, 2004; 27(10): 2554 - 2559. [Full Text] [PDF]
|
|
|
|
|
|
C. F. Deacon Therapeutic Strategies Based on Glucagon-Like Peptide 1 Diabetes, September 1, 2004; 53(9): 2181 - 2189. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. L. Baggio, Q. Huang, T. J. Brown, and D. J. Drucker A Recombinant Human Glucagon-Like Peptide (GLP)-1-Albumin Protein (Albugon) Mimics Peptidergic Activation of GLP-1 Receptor-Dependent Pathways Coupled With Satiety, Gastrointestinal Motility, and Glucose Homeostasis Diabetes, September 1, 2004; 53(9): 2492 - 2500. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Harder, L. Nielsen, T. D.T. Thi, and A. Astrup The Effect of Liraglutide, a Long-Acting Glucagon-Like Peptide 1 Derivative, on Glycemic Control, Body Composition, and 24-h Energy Expenditure in Patients With Type 2 Diabetes Diabetes Care, August 1, 2004; 27(8): 1915 - 1921. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C M. B Edwards GLP-1: target for a new class of antidiabetic agents? J R Soc Med, June 1, 2004; 97(6): 270 - 274. [Full Text] [PDF]
|
|
|
|
|
|
S. Madsbad, O. Schmitz, J. Ranstam, G. Jakobsen, and D. R. Matthews Improved Glycemic Control With No Weight Increase in Patients With Type 2 Diabetes After Once-Daily Treatment With the Long-Acting Glucagon-Like Peptide 1 Analog Liraglutide (NN2211): A 12-week, double-blind, randomized, controlled trial Diabetes Care, June 1, 2004; 27(6): 1335 - 1342. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. D'Alessio and T. P. Vahl Glucagon-like peptide 1: evolution of an incretin into a treatment for diabetes Am J Physiol Endocrinol Metab, June 1, 2004; 286(6): E882 - E890. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. R. Druce, C. J. Small, and S. R. Bloom Minireview: Gut Peptides Regulating Satiety Endocrinology, June 1, 2004; 145(6): 2660 - 2665. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Damci, S. Yalin, H. Balci, Z. Osar, U. Korugan, M. Ozyazar, and H. Ilkova Orlistat Augments Postprandial Increases in Glucagon-like Peptide 1 in Obese Type 2 Diabetic Patients Diabetes Care, May 1, 2004; 27(5): 1077 - 1080. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. T. Bloomgarden Glycemic Treatment: Control of glycemia Diabetes Care, May 1, 2004; 27(5): 1227 - 1234. [Full Text] [PDF]
|
|
|
|
|
|
K. B. Degn, C. B. Juhl, J. Sturis, G. Jakobsen, B. Brock, V. Chandramouli, J. Rungby, B. R. Landau, and O. Schmitz One Week's Treatment With the Long-Acting Glucagon-Like Peptide 1 Derivative Liraglutide (NN2211) Markedly Improves 24-h Glycemia and {alpha}- and {beta}-Cell Function and Reduces Endogenous Glucose Release in Patients with Type 2 Diabetes Diabetes, May 1, 2004; 53(5): 1187 - 1194. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J. Meier, M. A. Nauck, D. Kranz, J. J. Holst, C. F. Deacon, D. Gaeckler, W. E. Schmidt, and B. Gallwitz Secretion, Degradation, and Elimination of Glucagon-Like Peptide 1 and Gastric Inhibitory Polypeptide in Patients with Chronic Renal Insufficiency and Healthy Control Subjects Diabetes, March 1, 2004; 53(3): 654 - 662. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Drucker Enhancing Incretin Action for the Treatment of Type 2 Diabetes Diabetes Care, October 1, 2003; 26(10): 2929 - 2940. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Chang, G. Jakobsen, J. Sturis, M. J. Smith, C. J. Bloem, B. An, A. Galecki, and J. B. Halter The GLP-1 Derivative NN2211 Restores {beta}-Cell Sensitivity to Glucose in Type 2 Diabetic Patients After a Single Dose Diabetes, July 1, 2003; 52(7): 1786 - 1791. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J. Meier, B. Gallwitz, S. Salmen, O. Goetze, J. J. Holst, W. E. Schmidt, and M. A. Nauck Normalization of Glucose Concentrations and Deceleration of Gastric Emptying after Solid Meals during Intravenous Glucagon-Like Peptide 1 in Patients with Type 2 Diabetes J. Clin. Endocrinol. Metab., June 1, 2003; 88(6): 2719 - 2725. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. M. Gribble, L. Williams, A. K. Simpson, and F. Reimann A Novel Glucose-Sensing Mechanism Contributing to Glucagon-Like Peptide-1 Secretion From the GLUTag Cell Line Diabetes, May 1, 2003; 52(5): 1147 - 1154. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. E. Mayo, L. J. Miller, D. Bataille, S. Dalle, B. Goke, B. Thorens, and D. J. Drucker International Union of Pharmacology. XXXV. The Glucagon Receptor Family Pharmacol. Rev., March 1, 2003; 55(1): 167 - 194. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Rolin, M. O. Larsen, C. F. Gotfredsen, C. F. Deacon, R. D. Carr, M. Wilken, and L. B. Knudsen The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta -cell mass in diabetic mice Am J Physiol Endocrinol Metab, October 1, 2002; 283(4): E745 - E752. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Reimann and F. M. Gribble Glucose-Sensing in Glucagon-Like Peptide-1-Secreting Cells Diabetes, September 1, 2002; 51(9): 2757 - 2763. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Elbrond, G. Jakobsen, S. Larsen, H. Agerso, L. B. Jensen, P. Rolan, J. Sturis, V. Hatorp, and M. Zdravkovic Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of a Single-Dose of NN2211, a Long-Acting Glucagon-Like Peptide 1 Derivative, in Healthy Male Subjects Diabetes Care, August 1, 2002; 25(8): 1398 - 1404. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Diabetes | Diabetes Care | Clinical Diabetes | Diabetes Spectrum |